Diagnosing patients with rare diseases through a combination of artificial intelligence, smart computing power and genetics. To make this innovative project by Radboudumc, BioProdict and Vartion possible, the European Regional Development Fund (EFRO) and the province of Gelderland are supporting the project ‘Diagnostics-in-3D’ with more than half a million euros.
Many little ones make one big one. This also applies to rare hereditary diseases. One rare disease, as the word suggests, is not very common. But add up the roughly 7,000 known rare diseases and it soon amounts to about eight percent of the population. In recent decades, global efforts traced the causes of all these rare diseases. At the moment, this is possible for about half of the people with such a rare disease. So not for the other half. These patients do not know what exactly causes their illness.
Radboudumc, together with the companies Bio-Prodict and Vartion from the Nijmegen region, aims to change this with the project "Diagnostics-in-3D". This project is financially supported by the European Regional Development Fund (EFRO), more specifically by OP Oost, thereby contributing to a structural strengthening of the economy in the provinces of Gelderland and Overijssel. Martijn Huijnen, theme Metabolic Diseases, in the Radboudumc will lead the project. The starting point is the genetic code of humans. That code consists of approximately three billion letters. Many letters are the same, but a significant portion differs from person to person. Put one genome (the total of all genetic information of a human) next to the other and you will see many differences.
The importance of a good diagnosis
Regional cooperation - also aimed at strengthening the innovative, economic structure - is obvious. Huijnen: “The Nijmegen-based company Bio-Prodict has developed software that has automated the prediction of the effect of mutations on proteins. By using anonymous patient data and AI from Radboudumc, major steps can be taken in predicting the effect of mutations on the 3D structure of a protein, and thus on its function. For this, the representation of the 3D protein data, the deep learning architecture to be used and the computing power will be optimized. Malden-based Vartion is a specialist in the latter area. This collaboration of a knowledge institute and companies should ncrease the number of diagnoses for rare diseases. This is important, not only because a correct diagnosis is essential for the development of a treatment, but also because it may affect decisions about future pregnancies. ”
Which difference has an effect?
Martijn Huijnen: “The problem in the search for the cause of a rare hereditary disease is that it is not easy to indicate which difference in the genome exactly causes the disease. Suppose you find 1000 genetic differences in someone compared to the standard, which of those differences exactly makes you sick? Most differences have no effect whatsoever. As proteins do the work in our body, it is interesting to see whether a genetic difference also leads to important changes in the associated protein, making it less effective. That could be the cause of the rare disease. ”
A protein is a string of amino acids that has been carefully folded. That folding - organic origami you could say - is essential for the function of the protein. It provides the "hands and feet" with which a protein makes contact with other proteins and can do its job. Any genetic difference that causes a change in the shape of the protein could well be the cause of the rare disease. “In this way, the cause of rare diseases is increasingly - and successfully - searched for,” says Huijnen. "In our "Diagnostics-in-3D "project, Bio-Prodict, Vartion and Radboudumc now want to automate and accelerate this approach. In doing so, we mainly focus on the rare diseases that cause intellectual disabilities, a subject in which we have already built up a great deal of expertise in Nijmegen.”
Related news items
Four new professors explain the need for cooperation in developmental neuroscience27 January 2021
In the past, developmental neuroscience was not a field in which people from different disciplines cooperated very much. However, in recent years, the approach has been gradually changing. Four newly appointed professors at Radboudumc/ the Donders Institute understand the importance of teaming up.read more
Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis25 January 2021
Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.read more
Oral health research makes significant impact at the 148th WHO Executive Board meeting25 January 2021
During the 148th session of the World Health Organization (WHO) Executive Board meeting, Member States passed a game-changing resolution on oral health. WHO Director General Dr Tedros Adhanom Ghebreyesus called it a “landmark resolution”.read more
Radboud Young Academy safeguards the future of science21 January 2021
New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.read more
Increase radio- and immunotherapy efficacy by targeting hypoxia21 January 2021
In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.read more
Radiation boost lowers risk of prostate cancer recurrence21 January 2021
An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.read more